Metabolic complications among persons with HIV in nigeria - weight gain following initiation of integrase strand transfer inhibitor (INSTI)-based antiretroviral therapy (art) is a major emerging…
Active Grant Awarded Last action
- Award ID
- R21TW012835
- Recipient
-
Aminu Kano Teaching Hospital UEI RD18JAB5M7S5
- Awarding agency
-
Fogarty International Center
National Institutes of Health, Department of Health and Human Services
- Obligated
- $232,347
Award facts
- Assistance listing
- 93.989 International Research and Research Training
- Completion date 22% complete
- Place of performance
- Nashville, TN 37203, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services National Institutes of Health Fogarty International Center awarded Aminu Kano Teaching Hospital a $232,347 grant on June 11, 2026, under the International Research and Research Training program (CFDA 93.989). Grant R21TW012835 funds clinical research on metabolic complications among persons with HIV in Nigeria, focusing on weight gain after initiation of integrase strand transfer inhibitor (INSTI)-based antiretroviral therapy (ART). The research tests whether substantial early weight gain on tenofovir/lamivudine/dolutegravir (TLD) is driven by distinct alterations in metabolic and lipid pathways, measuring effects on insulin resistance, blood pressure, dyslipidemia, and inflammation. Recipient-side work includes metabolic and lipid pathway analyses, participant recruitment and screening, and data collection. The project rationale relies on Nigeria's near-uniform TLD use and high volume of new HIV diagnoses, which removes the drug-history variation that confounds comparable U.S. studies.
The obligated amount is $232,347, and the period runs from the June 11, 2026 award date through an ultimate completion date of May 31, 2028. The place of performance is listed as Nashville, TN 37203, USA, while the described research is conducted in Nigeria.
Description
Metabolic complications among persons with HIV in nigeria - weight gain following initiation of integrase strand transfer inhibitor (INSTI)-based antiretroviral therapy (art) is a major emerging public health threat, significantly increasing risks for dyslipidemia, systemic inflammation, hypertension, diabetes, and cardiovascular disease among people with HIV (PWH) in both the united states (U.S.) and globally. Addressing this challenge is a priority for U.S. Health, as identifying why some individuals experience excessive weight gain (well beyond "return to health" weight gain) will enable earlier, targeted interventions in at-risk U.S. Populations. This research environment cannot be replicated in the U.S. Due to extreme clinical heterogeneity: the U.S. Food and drug administration (FDA) has approved 26+ individual ARV medications across 7 mechanistic classes, leading to diverse prescribing patterns in which only ~52% of patients follow recommended initial regimens. Furthermore, the median U.S. Art treatment duration is 9.8 years, creating a complex history of prior drug exposures that act as significant confounders in metabolic studies. In contrast, nigeria uniquely offers a high volume of new HIV diagnoses and a near-uniform use of TLD (TENOFOVIR/LAMIVUDINE/DOLUTEGRAVIR). This uniformity provides a unique natural laboratory that yields faster, more direct answers about metabolomic and lipidomic signatures by eliminating the noise introduced by varied drug histories. Consequently, these findings can be scaled and adapted globally, directly benefiting the U.S. By informing next-generation diagnostic tools, treatment strategies, and prevention modalities. We hypothesize that substantial early weight gain on TLD is driven by distinct alterations in metabolic and lipid pathways. To test this, we will: 1) determine the effect of substantial early weight gain on TLD on insulin resistance, blood pressure, dyslipidemia, and inflammation. We will enroll previously art-naïve patients who initiated TLD regimens (N=200 total) in northern nigeria and gained 10% body weight (N=100) over their first 12-24 months of therapy. 2) determine the metabolic and lipid pathways associated with weight gain during the first 12 months of TLD exposure using metabolomic and lipidomic profiling. We will enroll 60 art-naïve patients initiating TLD and collect longitudinal sociodemographic, behavioral, clinical, metabolomic, and lipidomic data, along with abdominal CT imaging, to characterize visceral adiposity, hepatic density, and alterations in carbohydrate and lipid metabolism among participants with differing weight trajectories.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Original award | $232,347 |
Quick answers
Who received award R21TW012835?
R21TW012835 was awarded to Aminu Kano Teaching Hospital by Fogarty International Center (National Institutes of Health) on June 11, 2026.
How much is award R21TW012835 worth?
$232,347 has been obligated on R21TW012835.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award